1. Home
  2. EFSI vs EDIT Comparison

EFSI vs EDIT Comparison

Compare EFSI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Financial Services Inc

EFSI

Eagle Financial Services Inc

N/A

Current Price

$34.62

Market Cap

185.5M

Sector

Finance

ML Signal

N/A

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

N/A

Current Price

$2.26

Market Cap

206.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EFSI
EDIT
Founded
1881
2013
Country
United States
United States
Employees
231
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
185.5M
206.0M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
EFSI
EDIT
Price
$34.62
$2.26
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$42.00
$4.92
AVG Volume (30 Days)
9.4K
1.6M
Earning Date
04-24-2026
03-09-2026
Dividend Yield
3.87%
N/A
EPS Growth
N/A
37.50
EPS
N/A
N/A
Revenue
N/A
$31,937,000.00
Revenue This Year
$31.93
N/A
Revenue Next Year
$4.38
N/A
P/E Ratio
$24.38
N/A
Revenue Growth
N/A
132.64
52 Week Low
$28.70
$0.91
52 Week High
$41.12
$4.54

Technical Indicators

Market Signals
Indicator
EFSI
EDIT
Relative Strength Index (RSI) 48.17 49.93
Support Level $34.09 $2.08
Resistance Level $39.57 $2.36
Average True Range (ATR) 0.88 0.17
MACD 0.19 -0.02
Stochastic Oscillator 78.72 44.97

Price Performance

Historical Comparison
EFSI
EDIT

About EFSI Eagle Financial Services Inc

Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: